参考文献
1: Bisht S, Feldmann G, Brossart P. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):777-88. doi: 10.1517/17425255.2013.791281. Epub 2013 Apr 16. Review. PubMed PMID: 23590356.
2: Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatol Surg. 2013 Jul;39(7):981-7. doi: 10.1111/dsu.12184. Epub 2013 Mar 6. Review. PubMed PMID: 23464361.
3: Mankal P, O'Reilly E. Sunitinib malate for the treatment of pancreas malignancies--where does it fit? Expert Opin Pharmacother. 2013 Apr;14(6):783-92. doi: 10.1517/14656566.2013.776540. Epub 2013 Mar 4. Review. PubMed PMID: 23458511.
4: Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat Rev. 2013 Nov;39(7):818-30. doi: 10.1016/j.ctrv.2013.01.004. Epub 2013 Feb 28. Review. PubMed PMID: 23455076.
5: Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2013 May;52(4):691-702. doi: 10.3109/0284186X.2012.752579. Epub 2013 Jan 3. Review. PubMed PMID: 23282114.
6: Gallucci G, Tartarone A, Tocchetti CG, Bochicchio AM, Coccaro M, Capobianco A, Maurea N, Improta G, Zupa A, Aieta M. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. Future Oncol. 2013 Jan;9(1):127-33. doi: 10.2217/fon.12.162. Review. PubMed PMID: 23252570.
7: Lele AV, Clutter S, Price E, De Ruyter ML. Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature. J Clin Anesth. 2013 Feb;25(1):47-51. doi: 10.1016/j.jclinane.2012.07.001. Epub 2012 Dec 16. Review. PubMed PMID: 23246982.
8: Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori. 2012 Sep-Oct;98(5):139e-142e. doi: 10.1700/1190.13216. Review. PubMed PMID: 23235770.
9: Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem. 2012;12(15):1649-59. Review. PubMed PMID: 22978339.
10: Sunitinib and pancreatic neuroendocrine tumours. More assessment needed. Prescrire Int. 2012 May;21(127):123-5. Review. PubMed PMID: 22827001.
11: Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 2012 Jun;7(2):117-25. doi: 10.1007/s11523-012-0220-2. Epub 2012 Jun 2. Review. PubMed PMID: 22661319.
12: Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. Cancer Treat Rev. 2013 May;39(3):230-40. doi: 10.1016/j.ctrv.2012.04.009. Epub 2012 May 28. Review. PubMed PMID: 22647546.
13: Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Review. PubMed PMID: 22607009.
14: Zhou A. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience. Asia Pac J Clin Oncol. 2012 Jun;8(2):132-44. doi: 10.1111/j.1743-7563.2012.01525.x. Review. PubMed PMID: 22524572.
15: Mateo J, Heymach JV, Zurita AJ. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther. 2012 Jun 1;16(3):151-61. doi: 10.2165/11632590-000000000-00000. Review. PubMed PMID: 22515658; PubMed Central PMCID: PMC3872147.
16: Kassem MG, Motiur Rahman AF, Korashy HM. Sunitinib malate. Profiles Drug Subst Excip Relat Methodol. 2012;37:363-88. doi: 10.1016/B978-0-12-397220-0.00009-X. Epub 2012 Mar 19. Review. PubMed PMID: 22469323.
17: Vázquez S, León L, Fernández O, Lázaro M, Grande E, Aparicio L. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Ther. 2012 Mar;29(3):202-17. doi: 10.1007/s12325-011-0099-9. Epub 2012 Feb 7. Review. PubMed PMID: 22328304.
18: Aparicio-Gallego G, Blanco M, Figueroa A, GarcÃa-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Antón-Aparicio L. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther. 2011 Dec;10(12):2215-23. doi: 10.1158/1535-7163.MCT-10-1124. Review. PubMed PMID: 22161785.
19: Hubner RA, Valle JW. Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther. 2011 Dec;11(12):1817-27. doi: 10.1586/era.11.171. Review. PubMed PMID: 22117148.
20: Aparicio LM, Pulido EG, Gallego GA. Sunitinib-induced asthenia: from molecular basis to clinical relief. Cancer Biol Ther. 2011 Nov 1;12(9):765-71. doi: 10.4161/cbt.12.9.18138. Review. PubMed PMID: 22045104.
